What did Oppenheimer say in the initial coverage on February 05, 2026?

Oppenheimer initiated Whitehawk Therapeutics with an Outperform rating on February 05, 2026 and did not publish a price target. The note highlighted therapeutic potential and market positioning; TheFly summarized the initiation the same day.

How should investors interpret the WHWK analyst rating now?

Treat the WHWK analyst rating as a positive expert view, not a guarantee. Without a price target, the call is qualitative. Investors should follow catalysts, manage position size, and await follow-up research or clinical updates.

Did the market react to the Oppenheimer initiation and how?

Yes, the stock moved **-3.36% (-$0.10)** on the announcement date despite the Outperform. That decline highlights small-cap sensitivity and the importance of a published price target to shape immediate sentiment.

What does Meyka’s grade B mean for WHWK?

Meyka’s **B** grade reflects relative strengths versus the S&P 500 and sector peers, balanced by small-cap risks. The grade factors in analyst coverage, growth metrics, and market context but is not investment advice.

Analyst Ratings

Oppenheimer initiates Whitehawk Therapeutics (WHWK) with Outperform Feb 2026

ByHuzaifa Zahoor February 6, 2026

Oppenheimer on February 05, 2026 initiated coverage of Whitehawk Therapeutics Inc (WHWK) with an Outperform rating. This WHWK analyst rating establishes a positive baseline from a major research house and is the stock’s first formal coverage by a noted sell-side firm. The initiation cites growth potential while no price target was published. The research note coincided with a -3.36% (-$0.10) intraday move and follows a market cap of $127,717,861, highlighting the small-cap volatility investors should expect.